Elevating executive health with real-time molecular insight.
Executive and concierge health clinics are redefining prevention by offering comprehensive, personalized programs. Whole-body MRI, genomic testing, and lifestyle assessments provide valuable information but many clinics are now looking to add real-time biological signals that reflect what’s happening in the body today.
The miRoncol Real-time Multi-Cancer Early Risk Assessment offers exactly that: a simple blood-based test that integrates seamlessly into your clinic’s preventive health packages.
How It Fits Into Executive Programs
Annual assessments
Add molecular cancer risk testing alongside imaging, blood panels, and lifestyle reviews.
Longevity programs
Track evolving biological risk as part of age- and health-span monitoring.
Preventive packages
Offer peace of mind to clients who prioritize prevention, clarity, and confidence in health decisions.
Scientific Foundation
- Scientific studies based on 11,000+ human data across 12+ common solid tumours
- Specificity above 99% and sensitivity above 90% for many cancers
- Published in Cancers (2022) and Scientific Reports (2024)
- Recognized within the scientific community for innovation in early detection
Benefits
- Strengthens your clinic’s position as a leader in proactive health
- Offers clients peace of mind and meaningful early insight
- Provides a non-invasive, scalable, and repeatable test for ongoing monitoring
- Integrates smoothly with concierge and preventive care models
Limitations & Ethics
This is an early risk assessment tool, not diagnostic. Results should always be interpreted in collaboration with physicians and alongside conventional screenings.
Next Step
By incorporating miRoncol’s Real-time Multi-Cancer Early Risk Assessment, executive clinics can deliver a new dimension of prevention giving clients clarity today, and confidence in their future.
